| Literature DB >> 507257 |
Abstract
The paper provides an overview of public policy issues pertaining to the use of gene-splicing (recombinant DNA [deoxyribonucleic acid]) techniques in research and for industrial applications. Included is a discussion of the regulatory framework at the federal and institutional levels. The principal limitation of the current federal guidelines is its failure to provide mandatory coverage for private sector activities. Four municipalities and two states have passed their own legislation to remedy the situation. These enactments and their tie-in to the public health sector are examined.Keywords: NIH Guidelines; Recombinant DNA Advisory Committee
Mesh:
Substances:
Year: 1979 PMID: 507257 PMCID: PMC1619327 DOI: 10.2105/ajph.69.12.1252
Source DB: PubMed Journal: Am J Public Health ISSN: 0090-0036 Impact factor: 9.308